HAEMONETICS CORP

Key metrics

Financial performance

Over the last 15 fiscal years HAEMONETICS CORP's revenue grew from $676.69M to $1.33B, a compound annual growth rate of 4.6%. Net profit margin expanded from 4.4% to 7.3% over the same period - every figure below comes from the company's audited annual filings.

Key statistics

Latest filings

Browse the full filing history (1,875 filings)

Recent press releases

• Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website2026-05-07

  Financial release and supplemental presentation accessible online

• Haemonetics to Present at Bank of America 2026 Healthcare Conference2026-05-05

  The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/75d0U1.cfm .

• New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures2026-04-24

  New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

• Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 20262026-04-01

  The call can be accessed via teleconference at: Q4 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

• Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System2026-03-30

Similar companies

The largest companies sharing HAEMONETICS CORP's SEC industry classification (surgical & medical instruments & apparatus).